Dashboard
1
Poor Management Efficiency with a low ROCE of 2.78%
- The company has been able to generate a Return on Capital Employed (avg) of 2.78% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Poor long term growth as Net Sales has grown by an annual rate of -24.27% and Operating profit at -146.51% over the last 5 years
4
Negative results in Mar 25
5
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,290 Million (Small Cap)
2,827.00
NA
0.50%
0.51
0.02%
0.61
Revenue and Profits:
Net Sales:
1,781 Million
(Quarterly Results - Jun 2025)
Net Profit:
11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
34.84%
0%
34.84%
6 Months
28.15%
0%
28.15%
1 Year
17.99%
0%
17.99%
2 Years
6.32%
0%
6.32%
3 Years
-13.81%
0%
-13.81%
4 Years
9.01%
0%
9.01%
5 Years
-33.28%
0%
-33.28%
Realcan Pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-24.27%
EBIT Growth (5y)
-146.51%
EBIT to Interest (avg)
0.22
Debt to EBITDA (avg)
33.16
Net Debt to Equity (avg)
0.45
Sales to Capital Employed (avg)
0.60
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
80.29%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.78%
ROE (avg)
2.68%
Valuation key factors
Factor
Value
P/E Ratio
2827
Industry P/E
Price to Book Value
0.61
EV to EBIT
-138.14
EV to EBITDA
38.06
EV to Capital Employed
0.74
EV to Sales
0.81
PEG Ratio
NA
Dividend Yield
0.50%
ROCE (Latest)
-0.54%
ROE (Latest)
0.02%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
1,780.70
1,747.20
1.92%
Operating Profit (PBDIT) excl Other Income
31.00
116.70
-73.44%
Interest
42.40
75.50
-43.84%
Exceptional Items
0.00
-0.90
100.00%
Consolidate Net Profit
11.20
19.40
-42.27%
Operating Profit Margin (Excl OI)
-9.70%
39.10%
-4.88%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 1.92% vs -8.04% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -42.27% vs 273.21% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
7,929.40
7,988.70
-0.74%
Operating Profit (PBDIT) excl Other Income
220.30
103.80
112.24%
Interest
214.80
323.40
-33.58%
Exceptional Items
30.50
-266.10
111.46%
Consolidate Net Profit
41.00
32.00
28.12%
Operating Profit Margin (Excl OI)
0.50%
-17.70%
1.82%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -0.74% vs -34.84% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 28.12% vs 101.84% in Dec 2023
About Realcan Pharmaceutical Group Co., Ltd. 
Realcan Pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






